Adele joined TopiVert in October 2012 to direct preclinical development of the company’s advanced NSKIs and to act as Program Lead for Inflammatory Bowel Disease. She is also responsible for overall project portfolio strategy. Adele has over 20 years of drug discovery experience in the pharmaceutical and biotechnology industry ranging from target discovery and validation to early stage clinical development. She previously held the position of Director of Therapeutics at Cellzome in Cambridge, UK where she was a co-founder, and prior to this held roles of increasing responsibility at GlaxoSmithKline. Adele has a degree in Biology from the University of Bath and received her PhD in from Dalhousie University in Canada before undertaking postdoctoral studies at Cancer Research UK. She has authored over 20 scientific publications and is an elected fellow of The Royal Society of Biology. Adele joined TopiVert in October 2012 to direct preclinical development of the company’s advanced NSKIs and to act as Program Lead for Inflammatory Bowel Disease. She is also responsible for overall project portfolio strategy. Adele has over 20 years of drug discovery experience in the pharmaceutical and biotechnology industry ranging from target discovery and validation to early stage clinical development. She previously held the position of Director of Therapeutics at Cellzome in Cambridge, UK where she was a co-founder, and prior to this held roles of increasing responsibility at GlaxoSmithKline. Adele has a degree in Biology from the University of Bath and received her PhD in from Dalhousie University in Canada before undertaking postdoctoral studies at Cancer Research UK. She has authored over 20 scientific publications and is an elected fellow of The Royal Society of Biology.

fermentation